Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

juvenile absence epilepsy (JAE) - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

juvenile absence epilepsy

MONDO:0800453

Also known as:JAEepilepsy juvenile absence

Find Clinical TrialsTrials

Overview

A genetic epilepsy with onset occurring around puberty. Juvenile absence epilepsy is characterized by sporadic occurrence of absence seizures, frequently associated with a long-life prevalence of generalized tonic-clonic seizures (GTCS) and sporadic myoclonic jerks.

Treatments1 FDA approved

Clinical Trials3 registered · 1 recruiting

Diagnosis

Biomarker and diagnostic research for juvenile absence epilepsy has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for juvenile absence epilepsy, including ETHOSUXIMIDE (ZARONTIN, approved 1960). An additional 2 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Prognosis

Estimated prevalence: 1-9 in 100,000 (Uncommon).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

3 clinical trials registered, 1 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 3 PHASE3. Research is sponsored by a mix of industry and academic institutions.

30 publications have been identified in PubMed for juvenile absence epilepsy. Research spans Epidemiology / Natural History (33%), Basic Science / Preclinical (27%), and Review / Meta-Analysis (13%).

Research Type	Count	% of Total
Disease patterns and progression	10

Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 6:54 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:1941

GARD

Genetic and Rare Diseases Info Center

GARD:2162

Questions for Your Care Team

→What are the benefits and potential side effects of ZARONTIN for managing juvenile absence epilepsy?
→Are any of the 3 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
flunarizine	flunarizine	Xenon Pharmaceuticals Inc.	2022	—	Designated
brivaracetam	brivaracetam	UCB, Inc.	2019	—	Designated

Kisho

juvenile absence epilepsy

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

juvenile absence epilepsy

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications